Could you provide an overview of the Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment (DUET) ...
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the initiation of the Brilliance Studies, a phase 3 program evaluating the safety and efficacy of alixorexton compared to placebo ...
Alkermes plc (Nasdaq: ALKS) today announced the initiation of the Brilliance Studies, a phase 3 program evaluating the safety and efficacy of alixorexton compared to placebo in adults with narcolepsy ...
Eli Lilly has made yet another deal, this time buying a drug company that’s developing a therapy for narcolepsy for up to $7.8 billion. It’s acquiring Centessa Pharmaceuticals, which is working on ...
Eli Lilly plans to acquire Centessa Pharmaceuticals, which has been conducting a midstage clinical trial of its lead drug. By Rebecca Robbins Eli Lilly reached a deal on Tuesday to buy Centessa ...
Eli Lilly and Co. plans to buy Centessa Pharmaceuticals plc for $6.3 billion in up-front cash and another potential $1.5 billion through contingent value rights, gaining access to a pipeline of orexin ...
Going to graduate school can boost your career and salary — but some of the most popular advanced degrees are not worth the cost. That’s one of the main findings of a report released Tuesday by the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results